Supportive Care and Managing Toxicities Related to ADCs in TNBC

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Unadjusted post-recurrence OS was numerically lower with palbociclib plus endocrine therapy vs endocrine therapy alone in the phase 3 PALLAS trial.

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Data from the phase 3 PHILA study support pyrotinib plus trastuzumab as a therapeutic strategy in HER2-positive metastatic breast cancer.

Data from the PREFER study may provide evidence for improving oncofertility counseling for premenopausal women with early breast cancer.